Cytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on Thursday

Cytek Biosciences (NASDAQ:CTKB) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cytek Biosciences to post earnings of $0.02 per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Cytek Biosciences Price Performance

NASDAQ:CTKB opened at $4.20 on Thursday. Cytek Biosciences has a one year low of $2.37 and a one year high of $6.18. The business has a fifty day moving average price of $5.01 and a 200-day moving average price of $4.54. The firm has a market capitalization of $537.01 million, a price-to-earnings ratio of -42.00 and a beta of 1.30.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CTKB shares. Zacks Research cut Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Morgan Stanley initiated coverage on shares of Cytek Biosciences in a report on Monday, December 1st. They set an “equal weight” rating and a $6.00 price target on the stock. Piper Sandler dropped their price target on shares of Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Monday, December 29th. Finally, TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a research note on Thursday, January 8th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.50.

Hedge Funds Weigh In On Cytek Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of CTKB. Boston Partners bought a new position in shares of Cytek Biosciences during the third quarter valued at approximately $129,000. BNP Paribas Financial Markets boosted its holdings in Cytek Biosciences by 98.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 23,816 shares of the company’s stock valued at $83,000 after acquiring an additional 11,838 shares during the period. Quantbot Technologies LP grew its position in Cytek Biosciences by 37.1% in the 3rd quarter. Quantbot Technologies LP now owns 33,907 shares of the company’s stock valued at $118,000 after acquiring an additional 9,176 shares during the last quarter. Cerity Partners LLC purchased a new stake in Cytek Biosciences in the second quarter worth $175,000. Finally, Strs Ohio purchased a new stake in Cytek Biosciences in the first quarter worth $105,000. Institutional investors own 69.46% of the company’s stock.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.